Dr Annegret Van der Aa (CSO – CDO), Dr Kristof Van Emelen (Head of Medicinal Chemistry) and Dr Jean-Philip Herbeuval (Scientific founder) are co-author of “CXCR4 as a novel target in immunology: moving away from typical antagonists” published online in Future Drug Discovery (vol 4, n°2) – see link. This publication is at the cornerstone of Ermium CXCR4-specific immunomodulators and their uses in auto-immune diseases. It gathers scientists from Université Paris Cité, CNRS, University of Glasgow, and Ermium Therapeutics.
Menu
